Novo Nordisk to stop supplies of diabetes drug Ozempic to Russia this year

29 March 2023

Danish diabetes care giant Novo Nordisk (NOV: N) has announced it is terminating supplies of its Ozempic (semaglutide) to Russia at the end of the current year.

So far, the Russian drug regulator, Roszdravnadzor, has received a notification from Novo Nordisk about plans to stop deliveries of Ozempic, a type 2 diabetes treatment, to the Russian market starting from December, 2023, reports The Pharma Letter’s local correspondent.

In accordance with the Russian legislation the manufacturer is obliged to warn the authorities about the termination of supplies in advance in less than one year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK